Neurocrine Biosciences, Inc. (NASDAQ: NBIX) on Tuesday, plunged -1.28% from the previous trading day, before settling in for the closing price of $120.64. Within the past 52 weeks, NBIX’s price has moved between $103.63 and $157.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 34.77% over the last five years. The company achieved an average annual earnings per share of 99.31%. With a float of $98.77 million, this company’s outstanding shares have now reached $100.98 million.
The firm has a total of 1400 workers. Let’s measure their productivity. In terms of profitability, gross margin is 97.73%, operating margin of 25.7%, and the pretax margin is 21.09%.
Neurocrine Biosciences, Inc. (NBIX) Insider Activity
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Neurocrine Biosciences, Inc. is 2.19%, while institutional ownership is 93.04%. The most recent insider transaction that took place on Aug 15 ’24, was worth 2,090,332. In this transaction Director of this company sold 14,250 shares at a rate of $146.69, taking the stock ownership to the 37,491 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 11,570 for $150.43, making the entire transaction worth $1,740,450. This insider now owns 119,047 shares in total.
Neurocrine Biosciences, Inc. (NBIX) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.82 earnings per share (EPS) for the period falling under the consensus outlook (set at 0.97) by -0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 99.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.80% during the next five years compared to 62.04% growth over the previous five years of trading.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Trading Performance Indicators
Neurocrine Biosciences, Inc. (NBIX) is currently performing well based on its current performance indicators. A quick ratio of 4.08 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.67. Likewise, its price to free cash flow for the trailing twelve months is 24.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.31, a number that is poised to hit 1.53 in the next quarter and is forecasted to reach 6.88 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc. (NBIX)
Analysing the last 5-days average volume posted by the [Neurocrine Biosciences, Inc., NBIX], we can find that recorded value of 1.26 million was better than the volume posted last year of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 4.34%. Additionally, its Average True Range was 4.97.
During the past 100 days, Neurocrine Biosciences, Inc.’s (NBIX) raw stochastic average was set at 2.65%, which indicates a significant decrease from 2.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.14% in the past 14 days, which was higher than the 44.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $142.21, while its 200-day Moving Average is $136.07. Now, the first resistance to watch is $120.56. This is followed by the second major resistance level at $122.03. The third major resistance level sits at $123.29. If the price goes on to break the first support level at $117.84, it is likely to go to the next support level at $116.58. Should the price break the second support level, the third support level stands at $115.11.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Key Stats
Market capitalization of the company is 12.03 billion based on 100,637K outstanding shares. Right now, sales total 1,887 M and income totals 249,700 K. The company made 590,200 K in profit during its latest quarter, and 65,000 K in sales during its previous quarter.
